Faruqi & Faruqi Urges Kyverna Investors to Participate in Class Action Lawsuit by February 2025

Faruq & Faruq Calls for Kyverna Investors' Attention

In a recent announcement, Faruqi & Faruqi, LLP, a prominent national securities law firm, has reached out to investors of Kyverna Therapeutics, Inc. This call to action emphasizes the importance of participating in a pending class action lawsuit. The deadline for potential lead plaintiffs to step forward is set for February 7, 2025, revealing a critical window for those impacted by significant financial losses.

This legal investigation stems from allegations suggesting that Kyverna Therapeutics may have misled investors during its initial public offering (IPO) held around February 8, 2024. The firm highlights that investors who experienced losses exceeding $50,000 related to Kyverna’s common stock might be eligible to take action. Faruqi & Faruqi is particularly focused on claims that accuse Kyverna and its executives of breaching federal securities laws through their IPO registration statement and prospectus, which allegedly misstated and omitted critical information pertaining to clinical trial results of their drug candidates.

Specifically, it is claimed that Kyverna suggested improvements in patient outcomes related to KYV-101 trials, while failing to disclose concerning adverse data that the company was aware of at the time of the IPO. As these realities came to light, Kyverna's stock, which was initially sold at inflated prices, experienced a sharp decline of over 82%, dropping to a low of approximately $3.92 per share. This drastic fall reveals the potential financial repercussions for investors misled during the IPO process.

Faruqi & Faruqi's Securities Litigation Partner, James (Josh) Wilson, urges those affected to discuss their legal options. He can be contacted directly at either of the provided phone numbers for further guidance. The firm also encourages any individuals with additional information regarding Kyverna's actions, including whistleblowers and former employees, to reach out.

The court process will appoint a lead plaintiff, representing the financial best interests of the investor class, to oversee the litigation moving forward. Participation as a lead plaintiff does not impact the ability to claim a share of any potential recovery; however, it allows for greater involvement in directing the case against Kyverna. Investors remain encouraged to act promptly, as the forthcoming deadline approaches, ensuring they protect their rights in what could be a significant legal win for those defrauded.

To learn more about the class action lawsuit against Kyverna Therapeutics, investors can visit the Faruqi & Faruqi website at www.faruqilaw.com/KYTX. As details continue to emerge, investors can also follow ongoing updates via the firm’s LinkedIn, Twitter, or Facebook pages. Faruqi & Faruqi remains committed to advocating for justice for investors in this troubling case.

Attorney Advertising: The law firm responsible for this press release is Faruqi & Faruqi, LLP. Note that past results do not guarantee similar outcomes in future cases. Regardless, they welcome discussions regarding specific cases and promise confidentiality in all communications.